A daily briefing: new research, trials, the drug pipeline, funding and the news, compiled from the public registries and the open web
On May 22, 2026 in pancreatic cancer research
Why this new record; KRAS
7 papers published and 1 trial registered in the last 30 days were added on this day. Change tracking began 4 November 2026, so changes to older records aren't known for this day. The topic with the most new records was KRAS (1).
New trial
Why it was picked newest record on or before this date
New trial
Why it was picked newest record on or before this date
New paper
Why it was picked newest record on or before this date
New trial
Why it was picked newest record on or before this date
New paper
Why it was picked newest record on or before this date
New paper
New paper
New paper
New paper
Compiled by the knowledge layer from its change log. Every headline opens the underlying record; every identifier links to its source.
Change tracking began 4 November 2026, after this day, so retractions before then are not recorded by day.
From the web (not verified)
These links come from a web search. They have not been checked against our records; open the source before relying on them. They are what the search finds now, not what was news on that day.
Drug approvals here come from the web only and are not verified: our records don’t include regulatory (FDA) data yet.
Gifts from organizations only; individual donors aren’t listed.
79 Phase 3 (final-stage) pancreatic cancer trials are open or about to open: 49 recruiting, 14 not yet recruiting and 16 running, no longer recruiting. Trial records as of 8 November 2026.
daraxonrasib · in 4 trials
Everolimus · in 3 trials
Lanreotide · in 2 trials
RMC-9805 · in 2 trials
Cabozantinib · in 1 trial
Panitumumab · in 1 trial
Quemliclustat · in 1 trial
Setidegrasib · in 1 trial
Standard chemotherapy drugs (such as gemcitabine, paclitaxel, fluorouracil and oxaliplatin) are part of 21 of these trials and are left out of the list. 42 trials have no drug linked in the records; they may test surgery, radiation or a device, or a drug not yet matched to a name.
Counts are trials whose titles name the drug or target, so a few may be missed or counted twice. A trial that reached Phase 3 also counts as having reached Phase 2.
Approvals These records hold no drug-approval (regulatory) data, so this briefing can’t say whether any drug here is approved. A registry status of “approved for marketing” on an expanded-access record (a program that gives a drug to patients outside a trial) is not an FDA approval: Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma NCT07573215↗ . Web reports of approvals appear under In the news, not checked.
Who pays for pancreatic cancer research, and where the money is thin
NIH dollars by year are charted under The field at a glance.
Money counted here comes from the NIH (33 funding records: its institutes, centers and offices), CDMRP (US Department of Defense) Pancreatic Cancer Research Program, Lustgarten Foundation, PanCAN (Pancreatic Cancer Action Network) and Stephenson Institute.
What’s counted NIH awards, fiscal years 2003–2026, plus verified awards from Congressionally Directed Medical Research Programs - Pancreatic Cancer Research Program, Lustgarten Foundation, Pancreatic Cancer Action Network, Stephenson Global Pancreatic Cancer Research Institute. Not covered: DoD beyond CDMRP awards listed, industry, non-US public funders. Years outside that window are left out rather than shown as unfunded. Gifts from individual donors are not tracked; only awards from organizations are listed.
Awards carry only a year, not a day, so “newest” is by award year. How many awards we hold: CDMRP (US Department of Defense) Pancreatic Cancer Research Program 2; Lustgarten Foundation 44; PanCAN (Pancreatic Cancer Action Network) 235; Stephenson Institute 9.
Research areas with the most papers and trials but no counted grant money in 2021–2025 (full years only; 2026 is partial (to date) and left out):
G12D-targeted: 93 papers and 48 trials in 2021–2025, with $0 in counted grant money.
CLDN18.2 cell therapy & bispecifics: 12 papers and 10 trials in 2021–2025, with $0 in counted grant money.
Pan-RAS / multi-KRAS: 11 papers and 6 trials in 2021–2025, with $0 in counted grant money.
CLDN18.2 testing: 5 papers and 1 trial in 2021–2025, with $0 in counted grant money.
Anti-CLDN18.2 antibodies: 2 papers and 1
All pancreatic cancer research in our records, year by year
Researchers published 4,936 papers tagged pancreatic cancer in 2025, up 12% from 2024. In 2026, partial (to date): 5,071 so far. 393 trials tagged pancreatic cancer started in 2025, down 5% from 2024. In 2026, partial (to date): 400 so far. NIH put $325.8 million (dollars counted) into grants tagged pancreatic cancer in fiscal year 2025, up 4% from 2024. In 2026, partial (to date): $282.9 million so far.
papers tagged pancreatic cancer, by publication year.
trials tagged pancreatic cancer, by start year.
NIH dollars counted on grants tagged pancreatic cancer, by fiscal year (multi-year awards spread over their years, double counting removed).
These counts cover records tagged pancreatic cancer in our public sources, as of 2026-11-08. 96% of papers have a PubMed ID and 56% list every author. The latest year is always incomplete: journals and registries keep adding records for months. What counts as pancreatic cancer here: Every pancreatic cancer record from the source searches, plus trials with a stated pancreatic cohort, plus papers the field lane adds outside the title search (gated at collection by rule:field_relevance@1, precision 36/36 on a blind sample; docs/eval/field_lane.md).
1,059 trials tagged pancreatic cancer are recruiting patients now, and 330 more are about to start (not yet recruiting). Of these, 49 recruiting and 14 not-yet-recruiting trials are Phase 3 (final-stage), the last step before a drug can be approved.
| Phase | Recruiting | Not yet recruiting |
|---|---|---|
| Early Phase 1 (very first, small tests) | 27 | 13 |
| Phase 1 (first tests in people) | 194 | 43 |
| Phase 1/2 (first tests, then does it work?) | 169 | 35 |
| Phase 2 (does it work?) | 164 | 72 |
| Phase 2/3 (does it work, then final-stage) | 19 | 5 |
| Phase 3 (final-stage) | 49 |
Areas are approaches tagged by keyword rules; a record can be in more than one. Counted money here is grants tagged to the area, which in practice means NIH: foundation awards carry no area tags.
| 14 |
| Phase 4 (after approval) | 8 | 5 |
|---|
| No phase (device, diet or procedure studies) | 203 | 74 |
|---|
| Observational (watching patients, no treatment given) | 226 | 69 |
|---|
| All open trials | 1,059 | 330 |
|---|
May 16 – May 22 · the 7 days ending on this edition’s date
The registries added 61 new papers and 2 new trials this week. Change tracking began 4 November 2026, after these days, so changes to older records (status, results, retractions) aren't known for this week.
Showing the 8 most notable of 9 new trials in this week’s digests (ranked by the digest’s novelty score).
Change tracking began 4 November 2026, after these days, so newly posted results aren’t known for this week.
Change tracking began 4 November 2026, after these days, so status changes aren’t known for this week.
No new grants were listed in these seven days.